Weekly Biotech Catalysts
Every Sunday: the coming week of FDA decision dates, Phase 2 and 3 trial completions and earnings, plus the past week of delays, discontinuations, FDA decisions and new timelines from SEC filings.
Biotech Catalysts This Week: 4 Trial Completions, 15 Earnings Reports and 10 New Financings (Nov 15-22, 2026)
Biotech catalysts, Nov 15 to Nov 22, 2026: no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion, 15 earnings reports and 10 new…
Biotech Catalysts This Week: 3 FDA Decisions, 3 Trial Completions and 15 Earnings Reports (Nov 8-15, 2026)
Biotech catalysts, Nov 8 to Nov 15, 2026: 3 FDA decision dates, 3 Phase 2 or 3 trials reaching primary completion, 15 earnings reports and 10 new financing…
Biotech Catalysts This Week: 12 Trial Completions, 9 Earnings Reports and 10 New Financings (Nov 1-8, 2026)
Biotech catalysts, Nov 1 to Nov 8, 2026: no FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 9 earnings reports and 10 new financing…
Biotech Catalysts This Week: 2 FDA Decisions, 12 Trial Completions and 2 Earnings Reports (Oct 25-Nov 1, 2026)
Biotech catalysts, Oct 25 to Nov 1, 2026: 2 FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 2 earnings reports and 10 new financing…
Biotech Catalysts This Week: 4 Trial Completions and 9 New Financings (Oct 18-25, 2026)
Biotech catalysts, Oct 18 to Oct 25, 2026: no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion and 9 new financing filings.
Biotech Catalysts This Week: 1 FDA Decision, 1 Trial Completion and 8 New Financings (Oct 11-18, 2026)
Biotech catalysts, Oct 11 to Oct 18, 2026: 1 FDA decision date, 1 Phase 2 or 3 trial reaching primary completion and 8 new financing filings.
Biotech Catalysts This Week: 1 Trial Completion and 10 New Financings (Oct 4-11, 2026)
Biotech catalysts, Oct 4 to Oct 11, 2026: no FDA decision dates, 1 Phase 2 or 3 trial reaching primary completion and 10 new financing filings.
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 27–Oct 4, 2026)
No FDA decision dates fall in this week, so the calendar belongs to trials: seven company-led studies have estimated primary completion dates, among them IBRX’s BCG combination in bladder cancer, ARWR’s ARO-DIMERPA in mixed hyperlipidemia and JAZZ’s zanidatamab combination. On the financing side, VKTX filed $275M of convertible notes, and it was also last week’s […]
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 20–Sep 27, 2026)
Here’s what’s on the biotech calendar for September 20–September 27: 2 FDA decision dates, 1 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-09-22 IONS — NDA 2026-09-26 MIRM — NDA 🧪 Trial Catalysts & Milestones CRDL, 2026-09-21: CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) […]
Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 13–Sep 20, 2026)
Here’s what’s on the biotech calendar for September 13–September 20: 1 FDA decision dates, 2 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-09-18 NUVL — adult patients with locally advanced or metastatic ROS1-posi NDA 🧪 Trial Catalysts & Milestones VRTX, 2026-09-17: An Efficacy, […]